The
study analyzed that the Alzheimer's disease pipeline
comprises 89 drug candidates, of which 17 products are in Phase III, 28
products are in Phase II, 28 products are in Phase I, 15 products are in Pre-Clinical
stage and one product is in Discovery stage. Alzheimer’s disease is a common type of dementia
and a fatal illness. It includes memory loss and loss of
other intellectual abilities, which results in serious interference with the
patient’s daily activities. Around 60% to 80% of dementia cases turn out to be
Alzheimer’s disease and can cause problems with behavior, thinking and memory.
Symptoms usually develop at a slower rate initially and becoming worse with
time. Invasion of combination therapies, such as AVP-786, combination of
deuterium modified dextromethorphan and ultra-low dose quinidine and use of
various targets including amyloid- beta protein, tau protein is expected to
provide an effective and concrete treatment for the disease, with latest
technological advancements further adding to the pipeline growth.
Browse
Report Overview at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis
Insights
on pipeline segments
As
per the findings of the research, around 48.0% active drug candidates of
Alzheimer’s disease pipeline are being developed to be administered by oral
route, 8.0% by intravenous route, 6.0% are being developed to be administered
by subcutaneous route, 3.0% are being developed to be administered by
parenteral route and 6.0% are being developed to be administered by other
routes which include intranasal, inhalation and intravenous or subcutaneous.
Most of the drug candidates are being developed to be administered by oral
route, due to high patient compliance. Route of administration of around 29.0%
active drug candidates of Alzheimer’s disease pipeline are not disclosed.
Several companies are
involved in the development of Alzheimer’s disease pipeline, with their
products in different phases. Genentech, Inc., Eisai Co., Ltd. and AstraZeneca
plc, each have their drug candidates in Phase III stage of development. Eli
Lilly and Company is developing six products, out of which five are in Phase I
and one is in Phase II stage.
Major companies
collaborate for the development of Alzheimer’s disease pipeline
The research finds that different companies have collaborated
for the development of Alzheimer’s disease pipeline. In March 2014, Eisai Co.,
Ltd. and Biogen Idec collaborated to develop and commercialize two of Eisai's
clinical candidates, E2609 and BAN2401, for Alzheimer’s disease. Also, in April
2009, Bristol-Myers Squibb Company entered an agreement with Otsuka
Pharmaceutical Co., Ltd. to extend the U.S. portion of the companies’
long-standing agreement for the development and commercialization of ABILIFY
(aripiprazole).
Some
of the key players developing drugs for Alzheimer’s disease are Eli Lilly and
Company, Genentech, Inc., Eisai Co., Ltd., Bristol-Myers Squibb Company, Biogen
Idec, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis
Pharmaceuticals Corporation, AC Immune SA, Heptares Therapeutics and Probiodrug
AG.
No comments:
Post a Comment